TP53 and colorectal carcinoma: This was confirmed in a retrospective cohort including localized and advanced CRC, where FBXW7 mutations correlated with reduced DFS in stage III–IV disease (p = 0.002), although mutually exclusive TP53 and FBXW7 alterations were also noted [93].